Data regarding the prevalence of CDKN2A germline mutations in Brazilian patients fulfilling clinical criteria for familial melanoma are scarce; differ by geographic region and adopted diagnostic criteria; and disclose prevalence rates that vary from 4.5% to 14% [10–12]. This evidence concerns the gene CDKN2A and melanoma.